The malonyl CoA axis as a potential target for treating ischaemic heart disease

Cardiovascular Research

Volumn 79, Issue 2, 2008, Pages 259-268

  Ussher, John R ^a   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acetyl CoA carboxylase; AMP activated protein kinase; Fatty acid oxidation; Ischaemic heart disease; Malonyl CoA; Malonyl CoA decarboxylase

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MALONYL COENZYME A; MALONYL COENZYME A DECARBOXYLASE;

CARBOHYDRATE METABOLISM; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; ENERGY METABOLISM; FATTY ACIDS; HUMANS; MALONYL COENZYME A; MITOCHONDRIA; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 46749113468     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn130     Document Type: Review

References (92)

1. NHLBI Morbidity and Mortality Chart-book. Bethesda, MD: National Heart, Lung, and Blood Institute; 2004. http://www.nhlbi.nih.gov/resources/docs/ cht-book.htm (23 August 2007).
2. Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000;102:3137-3147.
3. Ussher JR, Lopaschuk GD. Clinical implications of energetic problems in cardiovascular disease. Heart Metab 2006;32:9-17.
4. Liu Q, Docherty JC, Rendell JC, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002;39:718-725.
5. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep 2005;7:63-70.
6. Folmes CD, Lopaschuk GD. Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. Cardiovasc Res 2007;73:278-287.
7. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263-276.
8. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
9. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789.
10. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996;79:940-948.
11. Dyck JR, Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol 2002;34:1099-1109.
12. Cuthbert KD, Dyck JR. Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation. Curr Hypertens Rep 2005;7:407- 411.
13. Neely JM, Morgan HE. Relationship between carbohydrate metabolism and energy balance of heart muscle. Annu Rev Physiol 1974;36:413-459.
14. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000;45:279-293.
15. Kunau WH, Dommes V, Schulz H. Beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Prog Lipid Res 1995;34:267-342.
16. Schulz H. Regulation of fatty acid oxidation in heart. J Nutr 1994;124:165-171.
17. Reszko AE, Kasumov T, Comte B, Pierce BA, David F, Bederman IR et al. Assay of the concentration and 13C-isotopic enrichment of malonylcoenzyme A by gas chromatography-mass spectrometry. Anal Biochem 2001;298:69-75.
18. Bianchi A, Evans JL, Iverson AJ, Nordlund AC, Watts TD, Witters LA. Identification of an isozymic form of acetyl-CoA carboxylase. J Biol Chem 1990;265:1502-1509.
19. Thampy KG. Formation of malonyl coenzyme A in rat heart. Identification and purification of an isozyme of A carboxylase from rat heart. J Biol Chem 1989;264:17631-17634.
20. Saddik M, Gamble J, Witters LA, Lopaschuk GD. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 1993;268:25836-25845.
21. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995;270:17513-17520.
22. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 2006;574:95-112.
23. Dyck JR, Barr AJ, Barr RL, Kolattukudy PE, Lopaschuk GD. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol 1998;275:H2122-H2129.
24. Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC et al. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 2005;289:H2304-H2309.
25. Dyck JR, Hopkins TA, Bonnet S, Michelakis ED, Young ME, Watanabe M et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 2006;114:1721-1728.
26. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 2004;94:e78-e84.
27. Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator- activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J 2004;378:983-990.
28. Young ME, Goodwin GW, Ying J, Guthrie P, Wilson CR, Laws FA et al. Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 2001;280:E471-E479.
29. Saha AK, Schwarsin AJ, Roduit R, Masse F, Kaushik V, Tornheim K et al. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside. J Biol Chem 2000;275:24279-24283.
30. Lysiak W, Toth PP, Suelter CH, Bieber LL. Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J Biol Chem 1986;261:13698-13703.
31. McGarry JD, Mills SE, Long CS, Foster DW. Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 1983;214:21-28.
32. Sacksteder KA, Morrell JC, Wanders RJ, Matalon R, Gould SJ. MCD encodes peroxisomal and cytoplasmic forms of malonyl-CoA decarboxylase and is mutated in malonyl-CoA decarboxylase deficiency. J Biol Chem 1999;274:24461- 24468.
33. Reszko AE, Kasumov T, David F, Jobbins KA, Thomas KR, Hoppel CL et al. Peroxisomal fatty acid oxidation is a substantial source of the acetyl moiety of malonyl-CoA in rat heart. J Biol Chem 2004;279:19574- 19579.
34. Whitmer JT, Idell-Wenger JA, Rovetto MJ, Neely JR. Control of fatty acid metabolism in ischemic and hypoxic hearts. J Biol Chem 1978;253:4305-4309.
35. Lorkovic H. Influence of changes in pH on the mechanical activity of cardiac muscle. Circ Res 1966;19:711-720.
36. Pannier JL, Leusen I. Contraction characteristics of papillary muscle during changes in acid-base composition of the bathing-fluid. Arch Int Physiol Biochim 1968;76:624-634.
37. Poole-Wilson PA, Langer GA. Effect of pH on ionic exchange and function in rat and rabbit myocardium. Am J Physiol 1975;229:570-581.
38. Solaro RJ, Lee JA, Kentish JC, Allen DG. Effects of acidosis on ventricular muscle from adult and neonatal rats. Circ Res 1988;63:779-787.
39. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res 2004;61:372-385.
40. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Yet al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998;1366:177-196.
41. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 1987;79:359-366.
42. Lopaschuk GD, Collins-Nakai R, Olley PM, Montague TJ, McNeil G, Gayle M et al. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J 1994;128:61-67.
43. Kurien VA, Oliver MF. Free fatty acids during acute myocardial infarction. Prog Cardiovasc Dis 1971;13:361-373.
44. Mueller HS, Ayres SM. Metabolic response of the heart in acute myocardial infarction in man. Am J Cardiol 1978;42:363-371.
45. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996;1301:67-75.
46. Sim AT, Hardie DG. The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. FEBS Lett 1988;233:294-298.
47. Baron SJ, Li J, Russell RR III, Neumann D, Miller EJ, Tuerk R et al. Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res 2005;96:337-345.
48. Beauloye C, Marsin AS, Bertrand L, Krause U, Hardie DG, Vanoverschelde JL et al. Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett 2001;505:348-352.
49. Russell R III. Stress signaling in the heart by AMP-activated protein kinase. Curr Hypertens Rep 2006;8:446-450.
50. Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114:495-503.
51. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005;11:1096-1103.
52. Zarrinpashneh E, Carjaval K, Beauloye C, Ginion A, Mateo P, Pouleur AC et al. Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol 2006;291:H2875-H2883.
53. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 2006;281:25336-25343.
54. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA 2006;103:17378-17383.
55. Altarejos JY, Taniguchi M, Clanachan AS, Lopaschuk GD. Myocardial ischemia differentially regulates LKB1 and an alternate 5′-AMP-activated protein kinase kinase. J Biol Chem 2005;280:183-190.
56. Sakamoto K, Zarrinpashneh E, Budas GR, Pouleur AC, Dutta A, Prescott AR et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 2006;290:E780-E788.
57. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-1156.
58. Timmer JR, van der Horst IC, Ottervanger JP, De Luca G, van't Hof AW, Bilo HJ et al. Glucose-insulin-potassium infusion as adjunctive therapy in myocardial infarction: current evidence and potential mechanisms. Ital Heart J 2004;5:727-731.
59. Yusuf S, Mehta SR, Diaz R, Paolasso E, Pais P, Xavier D et al. Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J 2004;148:1068-1078.
60. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin regulation of 5′-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ Res 2006;99:61-68.
61. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-446.
62. Diaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007;298:2399-2405.
63. Choi CS, Savage DB, Abu-Elheiga L, Liu ZX, Kim S, Kulkarni A et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA 2007;104:16480-16485.
64. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, Shaikenov TE et al. Liverspecific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA 2006;103:8552-8557.
65. Oh W, Abu-Elheiga L, Kordari P, Gu Z, Shaikenov T, Chirala SS et al. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice. Proc Natl Acad Sci USA 2005;102:1384-1389.
66. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001;291:2613-2616.
67. Zhang D, Liu ZX, Choi CS, Tian L, Kibbey R, Dong J et al. Mitochondrial dysfunction due to long-chain acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci USA 2007;104:17075-17080.
68. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008;7:45-56.
69. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002;277:4098-4103.
70. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 2006;290:H87-H95.
71. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptorgamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002;51:1507-1514.
72. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003;108:2393- 2399.
73. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005;46:1086-1092.
74. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-339.
75. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-1178.
76. Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007;3:33-39.
77. Sugden MC, Holness MJ. Potential role of peroxisome proliferator- activated receptor-alpha in the modulation of glucose-stimulated insulin secretion. Diabetes 2004;53(Suppl. 1):S71-S81.
78. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; CD003614.
79. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990;81:1260-1270.
80. Unger SA, Robinson MA, Horowitz JD. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med 1997;27:24-28.
81. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-3288.
82. Wargovich TJ, MacDonald RG, Hill JA, Feldman RL, Stacpoole PW, Pepine CJ. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988;61:65-70.
83. Yano S, Sweetman L, Thorburn DR, Mofidi S, Williams JC. A new case of malonyl coenzyme A decarboxylase deficiency presenting with cardiomyopathy. Eur J Pediatr 1997;156:382-383.
84. Greaves P, Martin J, Michel MC, Mompon P. Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism. Arch Toxicol Suppl 1984;7:488-493.
85. Higgins AJ, Faccini JM, Greaves P. Coronary hyperemia and cardiac hypertrophy following inhibition of fatty acid oxidation. Evidence of a regulatory role for cytosolic phosphorylation potential. Adv Myocardiol 1985;6:329-338.
86. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 2005;66:454-461.
87. Turcani M, Rupp H. Modification of left ventricular hypertrophy by chronic etomixir treatment. Br J Pharmacol 1999;126:501-507.
88. de Wit MC, de Coo IF, Verbeek E, Schot R, Schoonderwoerd GC, Duran M et al. Brain abnormalities in a case of malonyl-CoA decarboxylase deficiency. Mol Genet Metab 2006;87:102-106.
89. Ficicioglu C, Chrisant MR, Payan I, Chace DH. Cardiomyopathy and hypotonia in a 5-month-old infant with malonyl-coa decarboxylase deficiency: potential for preclinical diagnosis with expanded newborn screening. Pediatr Cardiol 2005;26:881-883.
90. Gao J, Waber L, Bennett MJ, Gibson KM, Cohen JC. Cloning and mutational analysis of human malonyl-coenzyme A decarboxylase. J Lipid Res 1999;40:178-182.
91. Matalon R, Michaels K, Kaul R, Whitman V, Rodriguez-Novo J, Goodman S et al. Malonic aciduria and cardiomyopathy. J Inherit Metab Dis 1993;16:571-573.
92. Wightman PJ, Santer R, Ribes A, Dougherty F, McGill N, Thorburn DR et al. MLYCD mutation analysis: evidence for protein mistargeting as a cause of MLYCD deficiency. Hum Mutat 2003;22:288-300.